GIPTIS (Genetics Institute for Patients, Therapies, Innovation & Science)

The majority of rare diseases are chronic disorders which are most often of genetic origin (in 80% of the cases) and mainly affect children (60%). Each disease is rare (1/2000 person), but together the rare disorders affect around 6-8% of the general population. The number of people suffering from rare diseases is estimated to be around 3 million in France, 50 million in the Mediterranean Basin, 25 to 30 million in Europe and 27 million in North America. But Less than 5 % of patients receive an adapted treatment! A new healthcare model > GIPTIS (Genetics Institute for Patients, Therapies, Innovation and Science) GIPTIS reinvents healthcare’s organizational model by placing patients affected with rare disease at the heart of a care and research loop to accelerate drug development, using an unprecedented public-private cooperation. The 3 main goals are: • Reduce diagnostic wavering • Improve global patient care • Reduce the drug development period to less than 10 years GIPTIS will gather in an unique place at the cutting edge of technology: private companies deeply associated to research projects, international & high potential researchers, healthcare professionals, technological resources centers, in-house support and drug development departments. The covered expertises will be: • From developmental biology to genetics of rare diseases • From epigenetics to genomes dynamics • From bioinformatics to system and integrative biology